Indivior PLC (NASDAQ:INDV) Shares Sold by Oaktree Capital Management LP

Oaktree Capital Management LP trimmed its holdings in Indivior PLC (NASDAQ:INDV - Free Report) by 8.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,733,548 shares of the company's stock after selling 788,432 shares during the quarter. Indivior makes up approximately 2.0% of Oaktree Capital Management LP's holdings, making the stock its 11th biggest position. Oaktree Capital Management LP owned 6.33% of Indivior worth $112,004,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of INDV. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Indivior in the 4th quarter valued at approximately $56,000. Stifel Financial Corp purchased a new stake in Indivior in the 3rd quarter valued at about $100,000. Melqart Asset Management UK Ltd purchased a new position in shares of Indivior during the third quarter worth approximately $132,000. Jane Street Group LLC purchased a new stake in shares of Indivior in the third quarter valued at approximately $180,000. Finally, Public Employees Retirement System of Ohio bought a new position in Indivior in the third quarter worth approximately $294,000. Institutional investors own 60.33% of the company's stock.

Indivior Trading Up 1.8 %

Shares of INDV stock traded up $0.17 during trading hours on Thursday, hitting $9.69. The company's stock had a trading volume of 515,585 shares, compared to its average volume of 899,268. The company has a 50 day moving average of $10.09 and a 200 day moving average of $10.37. The stock has a market cap of $1.34 billion, a PE ratio of -27.69 and a beta of 0.82. Indivior PLC has a 12-month low of $7.33 and a 12-month high of $22.53.

Remove Ads

Indivior (NASDAQ:INDV - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The company reported $0.32 EPS for the quarter, hitting the consensus estimate of $0.32. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. The business had revenue of $298.00 million for the quarter, compared to analyst estimates of $262.35 million. As a group, analysts anticipate that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Rodman & Renshaw began coverage on shares of Indivior in a research report on Tuesday, January 28th. They set a "buy" rating and a $16.00 target price on the stock. RODMAN&RENSHAW raised shares of Indivior to a "strong-buy" rating in a research report on Tuesday, January 28th. Finally, Piper Sandler lowered their target price on shares of Indivior from $16.00 to $13.00 and set an "overweight" rating for the company in a research note on Thursday, March 6th.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.